Previous 10 | Next 10 |
Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy PR Newswire ATLANTA , Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "C...
Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire ATLANTA , Sept. 7, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developin...
Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity PR Newswire ATLANTA , Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company ...
IRSA Propiedades Comerciales (IRCP) -69%.Infinity Pharmaceuticals (INFI) -23% on Q2 earnings release and updates data from bladder and breast cancer trials.TRxADE HEALTH (MEDS) -20% on Q2 earnings release.Bit Digital (BTBT) -17%.Flora Growth (FLGC) -15% to f...
Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients PR Newswire ATLANTA , July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pha...
Gainers: Clene (CLNN) +8%, Inhibikase Therapeutics (IKT) +7%, ASLAN Pharmaceuticals (ASLN) +5%, Doximity (DOCS) +5%.Losers: IMV (IMV) -26%, Tempest Therapeutics (TPST) -25%, Sonoma Pharmaceuticals (SNOA) -23%, Immunic (IMUX) -18%, Virpax ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks fell for a fourth straight day, and the S&P 500 finished its worst week since February, after St. Louis Federal Reserve President ...
Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock PR Newswire ATLANTA , June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics ...
Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...
Inhibikase Therapeutics (IKT) -24% after prices stock offering at $3Blue Apron Holdings (APRN) -19% after announcing share offering.Alfi (ALF) -14%.Clearside Biomedical (CLSD) -10%.TAL Education (TAL) -10%.TDH Holdings (PETZ) -10%.Unique Fabricating (UFAB) -9%.Roblox (RBLX...
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...